Episodios

  • The Future of Precision Medicine: How Biomarkers Can Guide Your Treatment

    The Future of Precision Medicine: How Biomarkers Can Guide Your Treatment
    Mar 24 2026
    What if a simple blood test could reveal how your body responds to disease - or even help doctors choose the right treatment for you? In this episode of Rx for Biotech, host Chris Leidli speaks with Mo Jain, MD, PhD, co-founder of Sapient, about how scientists are using advanced biology and artificial intelligence to uncover new biomarkers - the biological signals that can help doctors understand what’s happening inside the body. Biomarkers are becoming one of the most important tools in precision medicine, helping physicians move beyond one-size-fits-all treatments toward care that is tailored to each patient’s unique biology. Mo explains how Sapient is analyzing thousands of human samples using advanced technologies to better understand metabolism, disease progression, and how patients respond to therapies. These insights could help improve early diagnosis, guide treatment decisions, and empower patients with more personalized health information. In this conversation, you’ll learn: • What biomarkers are and why they matter for patients • How AI and advanced biology are helping scientists discover new health insights • Why understanding your body’s metabolism can change how diseases are treated • How biomarker data could help patients and doctors make better care decisions As medicine becomes more personalized, having the right biological information may become one of the most powerful tools patients have to advocate for their own care. For additional patient education and support, visit: https://therapy4me.ai
    Más Menos
    41 m
  • How Novartis is Changing Cancer Treatment and Putting Patients First in Modern Cancer Care

    How Novartis is Changing Cancer Treatment and Putting Patients First in Modern Cancer Care
    Mar 12 2026
    In this episode of "Rx for Biotech", host Chris Leidli speaks with Rodney Gillespie, Senior Vice President and U.S. Therapeutic Area Head for Oncology at Novartis, about the rapid evolution of prostate cancer care, including the rise of radioligand therapy and PSMA-targeted treatments like Pluvicto® (lutetium Lu 177 vipivotide tetraxetan). We discuss: * How PSMA-targeted radioligand therapy delivers radiation directly to cancer cells * The role of innovation in advanced and metastatic prostate cancer * Expanding patient access to cutting-edge therapies * Why patient advocacy and education matter in modern oncology As prostate cancer remains one of the most common cancers in men, new treatment approaches like radioligand therapy are redefining what’s possible for patients living with advanced prostate cancer.
    Más Menos
    27 m
  • Fixing the Body's Shield: A New Way to Fight Neurodegenerative Diseases

    Fixing the Body's Shield: A New Way to Fight Neurodegenerative Diseases
    Feb 11 2026
    What if helping the immune system find balance could meaningfully slow disease progression for diseases like ALS or Alzheimer’s? In this episode of Rx for Biotech, host Chris Leidli sits down with Arun Swaminathan, CEO of Coya Therapeutics, to talk about a new and hopeful approach to treating neurodegenerative diseases by calming harmful inflammation in the body. This conversation offers a hopeful look at how science is working to improve quality of life for patients and families facing neurodegenerative disease. Arun also shares insights from his 20+ years in biotech leadership, including what it takes to advance novel immunology science in high-unmet-need indications and build a product pipeline across neurodegenerative, autoimmune, and inflammatory diseases.
    Más Menos
    33 m
  • How to Advocate for Yourself in Cancer Care: Insights from a Top Oncologist

    How to Advocate for Yourself in Cancer Care: Insights from a Top Oncologist
    Jan 27 2026
    A cancer diagnosis can feel overwhelming - but patients are not powerless. In this episode, Dr. Nainesh Parikh of Moffitt Cancer Center explains how patients and families can better advocate for themselves, navigate complex healthcare systems, and get connected to the right care at the right time.
    Más Menos
    40 m
  • A New Hope for Skin Cancer: The Story Behind a Promising Immunotherapy

    A New Hope for Skin Cancer: The Story Behind a Promising Immunotherapy
    Jan 15 2026
    This episode is about hope, and about a different way of thinking about cancer treatment. My guest is Dr. Øystein Rekdal, CEO and co-founder of Lytix Biopharma. Øystein is a scientist and leader who has spent decades studying how the immune system works - and how it can be helped to recognize and fight cancer more effectively. Rather than focusing only on destroying tumors, Lytix is working on therapies designed to wake up the immune system and help it remember cancer as a threat. It’s an approach that aims not just to treat disease, but to support the body’s own ability to respond. This is a conversation for anyone who wants to better understand where cancer care is headed, and why there’s real reason for optimism.
    Más Menos
    34 m
  • Targeting the Fire Within: How InflaRx Is Redefining Inflammation Control

    Targeting the Fire Within: How InflaRx Is Redefining Inflammation Control
    Nov 20 2025
    InflaRx CEO Dr. Niels Riedmann joins Rx for Biotech to discuss how the company is pioneering complement-directed therapies to control severe inflammation and autoimmune disease. We break down the science behind INF904, and why C5a is such a powerful immune driver, and how precision immunology is shaping the next wave of treatment innovation.
    Más Menos
    35 m
  • How Novel Genetic Medicines may improve treatment of chronic Neurological Diseases

    How Novel Genetic Medicines may improve treatment of chronic Neurological Diseases
    Nov 11 2025
    In this episode of Rx for Biotech podcast, I speak with Philippe Chambon MD, PhD, CEO of EG 427, about how his company's HERMES technology platform could improve on the precision, durability and safety of gene therapy delivery. EG 427's lead candidate, EG110A, targets neurogenic bladder - a chronic condition linked to spinal cord injury, Parkinson's disease and multiple sclerosis - using a localized gene therapy designed to restore neuronal control with minimal side effects.
    Más Menos
    29 m
  • Restoring Breath: Biologic Innovation for the Most Vulenerable Patients

    Restoring Breath: Biologic Innovation for the Most Vulenerable Patients
    Oct 28 2025
    Airway Therapeutics is taking on one of the toughest challenges in medicine - helping premature infants breathe on their own. In this episode of Rx for Biotech, CEO Marc Salzberg shares how zelpultide alfa, an investigational, first-in-class biologic, could transform care for newborns with bronchopulmonary dysplasia (BPD) and unlock a new future for respiratory medicine.
    Más Menos
    21 m